Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

SK Biopharmaceuticals begin U.S. phase II trial of SKL-11197

Feb. 24, 2012

FDA advisory committee recommends approval of obesity therapy

Feb. 23, 2012

NICE confirms guidance on prolonged-release exenatide for type 2 diabetes

Feb. 23, 2012

Novel diacylglycerol O-acyltransferase 1 inhibitors synthesized

Feb. 23, 2012

Critical Pharma and U.K. university team up to develop nasal spray for osteoporosis

Feb. 21, 2012

Novel diacylglycerol O-acyltransferase 1 inhibitors synthesized by Sanofi

Feb. 21, 2012

FDA approves first medical therapy for endogenous Cushing's syndrome

Feb. 20, 2012

CHMP recommends approval of Byetta line extension

Feb. 20, 2012

Hyundai Pharmaceutical discloses new GPR119 receptor agonists

Feb. 20, 2012

Hanmi and AngioLab enter licensing agreement

Feb. 20, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...